SLC2A9 and Insulin resistance: In this study, pemafibrate may decrease serum UA by reducing over-expressed URAT1 and GLUT9 due to insulin resistance, and by improving systemic insulin resistance, which may be supported by a significant and positive correlation between changes in serum UA and changes in TG at 12 months after the start of pemafibrate.